Four Primary Mechanisms of Thrombocytopenia
Thrombocytopenia results from four distinct pathophysiologic pathways: (1) decreased platelet production, (2) increased platelet destruction, (3) splenic sequestration, and (4) dilutional thrombocytopenia. 1, 2, 3
1. Decreased Platelet Production
Bone marrow failure or suppression leads to inadequate megakaryocyte function and reduced platelet generation. 1
Mechanisms and Causes
Bone marrow disorders—including myelodysplastic syndromes, leukemias, aplastic anemia, and metastatic marrow infiltration—directly impair megakaryocyte differentiation and platelet release. 4, 1
Inherited thrombocytopenias—such as thrombocytopenia-absent radius syndrome, Wiskott-Aldrich syndrome, MYH9-related disease, and congenital amegakaryocytic thrombocytopenia—result from genetic defects in megakaryocyte lineage commitment, maturation, or platelet release. 4, 1, 5
Bone marrow suppression occurs with chronic alcohol use, certain medications (chemotherapy, antibiotics), viral infections (HIV, hepatitis C, parvovirus B19), and iron overload. 1, 6
Reduced thrombopoietin production in cirrhosis leads to decreased platelet generation; approximately 80% of cirrhotic patients have platelet counts below normal, though severe thrombocytopenia (<50 × 10⁹/L) is uncommon in compensated disease. 1, 6
Diagnostic Clues
Bone marrow examination is mandatory when age ≥60 years, systemic symptoms (fever, weight loss, bone pain), unexplained anemia or leukopenia, or atypical peripheral smear findings (immature cells, giant platelets) are present. 4, 1
Giant platelets approaching red-cell size on peripheral smear suggest inherited thrombocytopenias rather than acquired production defects. 4, 1
2. Increased Platelet Destruction
Accelerated platelet clearance—whether immune-mediated or non-immune—overwhelms compensatory bone marrow production. 1, 2, 3
Immune-Mediated Destruction
Primary immune thrombocytopenia (ITP) is an autoimmune disorder with antibody-mediated destruction of otherwise normal platelets, diagnosed only after excluding all secondary causes. 4, 1, 7
Secondary immune thrombocytopenia is associated with HIV, hepatitis C, Helicobacter pylori, systemic lupus erythematosus, antiphospholipid syndrome, lymphoproliferative disorders, and common variable immune deficiency. 4, 1
Drug-induced immune thrombocytopenia can occur with heparin (heparin-induced thrombocytopenia), glycoprotein IIb/IIIa inhibitors, quinine, sulfonamides, antibiotics, and certain chemotherapies, typically presenting 5–14 days after drug exposure. 4, 1
Heparin-induced thrombocytopenia (HIT) typically presents 5–10 days after heparin exposure with moderate thrombocytopenia (30–70 G/L) and paradoxical thrombosis risk (30–50%); the 4T score (thrombocytopenia degree, timing, thrombosis presence, absence of other causes) guides diagnosis, and anti-PF4 antibody testing is mandatory when the score is ≥4. 4, 1
Non-Immune Destruction
Thrombotic microangiopathies—including thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), and disseminated intravascular coagulation (DIC)—cause platelet consumption through microvascular thrombosis; untreated TTP carries >90% mortality. 4, 1
Consumption thrombocytopenia occurs with extracorporeal circuits, intra-aortic balloon pumps, and cardiac surgery with cardiopulmonary bypass. 1
Antiphospholipid syndrome causes thrombocytopenia with thrombosis rather than bleeding. 4, 1
Diagnostic Approach
Peripheral blood smear review by a hematopathologist is mandatory; schistocytes indicate thrombotic microangiopathy, requiring urgent ADAMTS13 activity, LDH, haptoglobin, and coagulation studies. 4, 1
HIV and hepatitis C testing is mandatory in all adults with suspected ITP, regardless of risk factors, because these infections can masquerade as primary ITP for years. 4, 1
Helicobacter pylori testing (urea-breath test or stool antigen) should be performed in adults with suspected ITP, as eradication normalizes platelet counts in a subset of patients. 4, 1
3. Splenic Sequestration
Portal hypertension and hypersplenism trap platelets in the enlarged spleen, reducing circulating platelet counts. 1, 2, 3, 6
Mechanisms
Portal hypertension associated with cirrhosis induces hypersplenism, leading to platelet sequestration; the degree of thrombocytopenia correlates with splenomegaly extent and portal pressure magnitude. 1, 6
Up to one-third of the total platelet mass can be sequestered in an enlarged spleen, compared to 10% in a normal spleen. 2, 3
Diagnostic Clues
Moderate or massive splenomegaly on physical examination excludes primary ITP and mandates investigation for chronic liver disease, portal hypertension, lymphoproliferative disorders, or myelofibrosis. 4, 1
Thrombocytopenia from splenic sequestration is typically mild to moderate (50–100 × 10⁹/L) and rarely causes bleeding unless additional factors (coagulopathy, platelet dysfunction) are present. 2, 3
4. Dilutional Thrombocytopenia
Massive fluid resuscitation or transfusion dilutes circulating platelets without altering total body platelet mass. 2, 3
Clinical Context
Dilutional thrombocytopenia occurs during massive transfusion protocols, large-volume crystalloid resuscitation in trauma or sepsis, and cardiopulmonary bypass surgery. 2, 3
Onset is typically within 1–3 days of the dilutional event, distinguishing it from immune-mediated causes that present 5–14 days after exposure. 1
Management Considerations
- Platelet transfusion is indicated when platelet counts fall below 50 × 10⁹/L in actively bleeding patients or below 10 × 10⁹/L in non-bleeding patients with dilutional thrombocytopenia. 2, 3
Critical Diagnostic Pitfalls
Never diagnose thrombocytopenia without hematopathologist review of the peripheral smear; automated counters miss pseudothrombocytopenia (EDTA-dependent platelet clumping) in approximately 0.1% of samples. 4, 1
Failure to recognize TTP, HIT, or DIC carries catastrophic mortality risk (untreated TTP >90% mortality; HIT thrombosis risk 30–50%); prompt exclusion via smear review, 4T-score calculation, and coagulation studies is essential. 4, 1
Missing secondary causes of ITP—such as HIV, hepatitis C, and H. pylori—which have different natural histories and responses to therapy, is a critical diagnostic error. 4, 1
Presence of splenomegaly, hepatomegaly, or lymphadenopathy excludes primary ITP and mandates investigation for HIV, systemic lupus erythematosus, lymphoproliferative disorders, or chronic liver disease. 4, 1